Cardinal Health, Inc. vs International Business Machines Corporation: Strategic Comparison

This in-depth comparison examines Cardinal Health, Inc. and International Business Machines Corporation across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Cardinal Health, Inc. on its own, evaluating International Business Machines Corporation, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Cardinal Health, Inc. and International Business Machines Corporation is widest.

On the headline numbers, Cardinal Health, Inc. reports annual revenue of $254.2B against $67.5B for International Business Machines Corporation, while their respective market capitalizations stand at $56.0B and $216.3B. Both Cardinal Health, Inc. and International Business Machines Corporation are headquartered in United States, so they compete in a shared home market and regulatory environment.

Cardinal Health, Inc.: Cardinal Health, based in Ohio, is one of the three large US pharmaceutical distributors, along with McKesson and Cencora. It does not invent drugs or treat patients. It runs the regulated supply chain that moves medicines and medical devices from manufacturers to pharmacies and hospitals, so a prescription collected at a local pharmacy has often passed through its network.

International Business Machines Corporation: IBM, nicknamed Big Blue, is one of the oldest technology companies still operating at scale. It missed the consumer internet and smartphone eras, sold its PC business to Lenovo in 2005, and spun off its managed infrastructure services unit as Kyndryl in 2021. What remains is a business-to-business company with four segments: Software, Consulting, Infrastructure, and Financing. In FY2025 it reported $67.5 billion in revenue and $10.6 billion in net income, with software the largest segment at about $30 billion. Its customers are mostly large banks, insurers, airlines, retailers, and governments that run critical systems on IBM Z mainframes and want help connecting those systems to public clouds and AI.

Cardinal Health, Inc. and International Business Machines Corporation pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Cardinal Health, Inc. and International Business Machines Corporation.

Cardinal Health, Inc. business model: The business model is large, high-volume logistics divided into two segments: Pharmaceutical and Medical. In the Pharma segment, they buy billions of dollars of drugs from manufacturers (like Pfizer) and distribute them daily to tens of thousands of pharmacies and hospitals, taking a tiny markup. In the Medical segment, they actually manufacture and distribute low-cost, high-volume medical supplies (like surgical gloves, gowns, and syringes), acting as the large central supply closet for the entire American hospital system.

International Business Machines Corporation business model: IBM makes money from four segments. Software ($29.96 billion in FY2025, about 44% of revenue) includes Red Hat Enterprise Linux and OpenShift, HashiCorp Terraform and Vault, Confluent data streaming (from March 2026), watsonx AI, automation, security, and mainframe transaction-processing software, sold mostly as subscriptions and recurring licenses. Consulting ($21.06 billion, about 31%) bills for strategy, technology implementation, and application management work, often deploying IBM and partner software. Infrastructure ($15.72 billion, about 23%) sells IBM Z mainframes, Power servers, storage, and related support; revenue rises sharply in the year after each new mainframe launch, such as the z17 in 2025. Financing ($0.74 billion) lends to clients buying IBM hardware and software.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Cardinal Health, Inc. stack up against those of International Business Machines Corporation.

Cardinal Health, Inc. competitive advantage: Cardinal Health's advantage is physical scale and regulatory standing. Moving regulated, temperature-sensitive drugs and biologics across the country overnight takes a network of specialized distribution centers and security procedures that cost billions of dollars and take decades to build. The barrier to entry is high, so drug distribution is concentrated among a few large companies.

International Business Machines Corporation competitive advantage: IBM's main advantage is how deeply it is built into the core systems of large regulated organizations. Banks, card networks, insurers, and governments run high-volume transaction processing on IBM Z, and moving those workloads is slow, risky, and expensive. On top of that installed base, Red Hat gives IBM a neutral hybrid cloud platform that runs on every major cloud, and IBM Consulting gives it a way to deliver software inside multi-year transformation projects. Few rivals combine mainframe hardware, open-source platform software, and a large consulting arm under one contract.

Future prospects matter as much as current results. The growth strategies below explain how Cardinal Health, Inc. and International Business Machines Corporation each plan to expand from here.

Cardinal Health, Inc. growth strategy: Cardinal Health's growth plan rests on three levers. First, specialty pharmaceuticals and physician practice platforms: it bought a 71% stake in GI Alliance for about $2.8 billion (announced November 2024) and funded The Specialty Alliance's roughly $1.9 billion acquisition of urology MSO Solaris Health (completed November 2025). Second, the Other segment: Nuclear and Precision Health Solutions (radiopharmaceuticals and theranostics), at-Home Solutions (expanded with ADSG in 2025, Strive Medical, and the announced AdaptHealth diabetes business), and OptiFreight Logistics, which together grew revenue 26% to $6.8 billion in fiscal 2026. Third, improving GMPD profitability through its Cardinal Health brand products and cost actions.

International Business Machines Corporation growth strategy: IBM does not try to beat AWS, Microsoft Azure, or Google Cloud at selling public cloud capacity. It sells the software layer that runs across all of them and across on-premises data centers. Red Hat OpenShift and RHEL run applications anywhere, HashiCorp (acquired February 2025 for $6.4 billion) automates and secures multi-cloud infrastructure, and Confluent (acquired March 2026 for about $11 billion) streams real-time data into AI applications and agents. watsonx and the open-source Granite models target regulated companies that want AI with governance and data control. Consulting brings this software into client projects, and IBM reported a generative AI book of business above $12.5 billion since inception. Longer term, IBM is betting on quantum computing, with a roadmap toward a fault-tolerant system later this decade.

A closer look at the financial trajectory of Cardinal Health, Inc. and International Business Machines Corporation rounds out the comparison.

Cardinal Health, Inc.: Cardinal Health combines very large revenue with thin margins. Fiscal 2026 revenue was $254.2 billion, up 14% from $222.6 billion in fiscal 2025, driven by brand and specialty drug volume from existing customers. GAAP operating earnings were $2.6 billion, GAAP diluted EPS was $7.23, and net earnings attributable to Cardinal Health were about $1.7 billion. Non-GAAP diluted EPS rose 37% to $11.26 ($10.95 excluding the IEEPA tariff refund). Operating cash flow was $5.2 billion and adjusted free cash flow was $5.0 billion. The company repurchased $1.4 billion of stock in fiscal 2026 and the board added $5.0 billion to the buyback authorization in August 2026. Fourth-quarter fiscal 2026 revenue was $63.7 billion, up 6%.

International Business Machines Corporation: IBM's reported revenue fell from about $80 billion in 2016-2018 to $57.4 billion in 2021, mostly because the Kyndryl spin-off and earlier divestitures removed low-margin services. Since then the slimmer company has grown each year: $60.5 billion in 2022, $61.9 billion in 2023, $62.8 billion in 2024, and $67.5 billion in 2025 (up 7.6%). FY2025 net income from continuing operations was $10.6 billion and free cash flow was $14.7 billion. In Q2 2026, revenue rose 1% to $17.16 billion: software grew 5% to $7.76 billion, consulting was flat at $5.33 billion, and infrastructure fell 7% to $3.84 billion as IBM Z sales lapped the z17 launch. Some large software deals slipped out of the quarter, so IBM cut its 2026 constant-currency revenue growth forecast to 4-5% while keeping its target of about $1 billion more free cash flow than in 2025.